Chronic kidney disease, systemic microvascular dysfunction and heart failure

Clicks: 6
ID: 337977
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #222 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract The high prevalence of cardiovascular disease and heart failure in people with chronic kidney disease (CKD) has conventionally been attributed to hypertension and epicardial coronary artery disease (CAD). Coronary artery occlusion may cause myocardial infarction and/or dysfunction, a reduced left ventricular ejection fraction (LVEF), and heart failure (HFrEF). Prolonged hypertension will lead to left ventricular hypertrophy and fibrosis, which may cause heart failure with a preserved LVEF (HFpEF), often in the absence of CAD. Systemic microvascular dysfunction may link hypertension, CKD, cardiometabolic disease, and heart failure; CKD may amplify this process, particularly in advanced disease, without necessarily being the initiating lesion. Prevention of end-stage kidney disease and heart failure is an important therapeutic goal for patients with hypertension and mild CKD, but event rates are low, requiring large, long-term trials to provide definitive evidence. Accordingly, CKD and HFpEF should be considered overlapping manifestations of systemic microvascular dysfunction, driven variably by CKD, cardiometabolic disease, or bidirectional cardiorenal interactions. Imaging markers of microvascular dysfunction and end-organ dysfunction should evolve from descriptive tools to mechanistic endpoints and potential therapeutic targets.
Reference Key
openalex_W7225000108 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Carmine Zoccali, Raffaele De Caterina, Francesca Mallamaci, John Cleland
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag387
URL
https://doi.org/10.1093/ckj/sfag387
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.